Galectin治疗 GALT 深 沪
等待开盘 05-21 09:30:00 美东时间
2.21
+0.130
+6.25%
华盛通- 最 高2.22
- 今 开2.11
- 成交量 17.47万股
- 最 低 2.08
- 昨 收 2.08
- 总市值 1.45亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.27
- 委 比 -99.84%
- 总股本 6582.74万
- 历史最高 19.11
- 量 比 0.54
- 振 幅 6.73%
- 历史最低 0.49
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per
05-15 20:13
Galectin Therapeutics Q1 FY26 net loss narrows to $5.1 million
Galectin Therapeutics Q1 FY26 net loss narrows to $5.1 million Galectin Therapeutics posted Q1 net loss applicable to common stockholders of $5.1 million, or $(0.08) per share, narrowing from a $9.6 million loss, or $(0.15) per share, a year earlier. R&D expense fell to $2.2 million from $6.5 millio
05-15 19:51
Galectin net loss narrows 47.61% to $5.05 million in Q1 FY26
Galectin net loss narrows 47.61% to $5.05 million in Q1 FY26 Galectin Therapeutics posted a net loss of USD 5.05 million, or USD 0.08 per share, for quarter ended March 31, 2026, narrowing from a net loss of USD 9.63 million, or USD 0.15 per share, a year earlier. Operating loss narrowed to USD 4.08
05-15 19:47
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics, Inc. reported progress on its belapectin program targeting galectin-3 in MASH cirrhosis, with positive biomarker data from the NAVIGATE trial showing reduced liver stiffness and slower disease progression. The company plans to present additional findings at EASL and meet with the FDA. Financially, as of Q1 2026, the company had $14.1 million in cash and a $10 million credit line, sufficient for operations through May 2027. ...
05-15 12:00
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Argenx reported $1.3 billion in Q1 2026 product net sales, up 63% YoY, with VYVGART driving growth. The PDUFA date for anti-AChR antibody negative gMG is May 10, 2026. Key highlights include advancing FcRn leadership in rheumatology, progressing empasiprubart in MMN, and expanding the pipeline with ten molecules in clinical development. The company also announced Karen Massey as CEO and expanded its presence in China. Financial results showed a 1...
05-07 05:00
Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share
03-31 22:19
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported that its belapectin program, targeting galectin-3, showed progress in reducing varices and positive biomarker data in patients with MASH cirrhosis. The company secured an additional $10 million line of credit, bolstered its board with Dr. Henry Brem, and saw improved financial stability with reduced R&D expenses, narrowing its net loss.
03-31 12:00
Galectin Therapeutics appoints Henry Brem to board as independent director
Galectin Therapeutics appoints Henry Brem to board as independent director Galectin Therapeutics appointed Henry Brem as an independent director to its board. Brem is the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurg
03-17 19:51
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Galectin Therapeutics Inc. appointed Henry Brem, M.D., as an independent director. Dr. Brem is a leading neurosurgeon-scientist with extensive experience in translational medicine, having developed image-guided surgical techniques and localized drug delivery systems. His expertise will support Galectin’s development of belapectin for patients with MASH cirrhosis and portal hypertension. The company continues to strengthen its board with scientifi...
03-17 12:00
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
argenx reported strong FY2025 financial results with $1.3B Q4 and $4.2B global product net sales, representing 90% YoY growth, and delivered $1.1B in operating income, marking its first year of operating profitability. Key highlights include VYVGART's label expansion, a PDUFA target date of May 10, 2026 for anti-AChR Ab-negative gMG, and strategic priorities to advance Vision 2030. argenx is expanding its impact in autoimmune diseases, advancing ...
02-26 06:00
